4811 results about "Blood plasma" patented technology

A catheter system (100) for treating a treatment site (106) within or adjacent to a vessel wall (108A) of a blood vessel (108) includes an energy source (124), an energy guide (122A), and a guidewire lumen (118). The energy source (124) generates energy. The energy guide (122A) is configured to selectively receive the energy from the energy source (124). The energy guide (122A) includes a guide distal end (122D). The energy that is received by the energy guide (122A) is emitted from the guide distal end (122D). The guidewire lumen (118) having an outer surface (218S). At least the guide distal end (122D) of the energy guide (122A) is positioned adjacent to the outer surface (218S) of the guidewire lumen (118) A portion of the guidewire lumen (118) encompasses a plasma generator (133) that is positioned near the guide distal end (122D) of the energy guide (122A). The plasma generator (133) is positionable near the treatment site (106). The plasma generator (133) is formed from a polymeric material.

The invention relates to the technical field of biomarkers, in particular to a blood biomarker combination for prediction and auxiliary diagnosis of ovarian reserve hypofunction (DOR), a corresponding detection kit and application of the blood biomarker combination. According to the invention, the content change of the nicotinamide mononucleotide (NMN) and the metabolite combination thereof in serum or plasma is screened for the first time and can be used as a detection index for predicting the ovarian reserve function decline. Based on the biomarker combination, the invention further provides an in-vitro detection kit containing a related standard substance, an internal standard solution and an extracting solution, and a data analysis method combined with a random forest model, so that an individual with a normal ovarian reserve function and an individual with hypofunction can be accurately distinguished. The method is noninvasive, simple, convenient, high in sensitivity and suitable for early recognition and layered screening of clinical ovarian reserve hypofunction.

The present invention relates to spray drying plasma methodology that includes pretreating a donated liquid plasma unit, drying the liquid plasma using a spray drying apparatus with the spray drying disposable device that results in a disposable having the dried plasma, finishing the disposable using the finishing apparatus that is designed to seal and separate the disposable, and transform the disposable into a dried plasma unit. The methods of the present invention include storing the dried plasma unit and, when ready for use, reconstituting the dried plasma unit with reconstitution solution to obtain a plasma unit ready for transfusion into a recipient.

The invention relates to a biotechnology, and particularly discloses a plasmin degradation product D-dimer antibody and application thereof. According to the application, a single B cell antibody preparation technology and a flow cytometry sorting method are applied to the development of a blood coagulation in-vitro diagnosis fibrinolysis system detection antibody for the first time, and a mammalian cell expression system (293F) is adopted to successfully express and obtain three strains of D-dimer monoclonal antibodies (antibody numbers are DD-1, DD-2 and DD-3) with biological activity. Compared with the on-sale Roch D-dimer antibody, the three antibodies have the same affinity with the DD antigen, and can identify and detect the D-dimer in plasma with high specificity and high sensitivity; meanwhile, the probe has no cross reaction with fibrinogen, primary fibrinolytic substances (X, Y and D) and soluble fibrin (SF), and can be used for qualitative or quantitative detection of D-dimer.

The invention provides conotoxin-derived anticoagulant polypeptide Cb-13 and application thereof, and belongs to the technical field of biological medicine. The invention provides an anticoagulant polypeptide Cb-13. The amino acid sequence of the anticoagulant polypeptide Cb-13 comprises SEQ ID No.1. The invention also provides a coding gene of the anticoagulant polypeptide Cb-13, and provides that the anticoagulant polypeptide Cb-13 does not have hemolytic activity and does not have cytotoxicity when the concentration is 400 [mu] M or below. The anticoagulant polypeptide Cb-13 disclosed by the invention has a prolonging effect on plasma recalcification and coagulation time, has an anticoagulant effect, has small influence on bleeding, and also has an obvious promoting effect on plasmin and uPa. Meanwhile, it is also proved that the anticoagulant polypeptide Cb-13 can inhibit thrombus formation, that is, the anticoagulant polypeptide Cb-13 has in-vivo and in-vitro fibrinolytic effect and anticoagulant effect, has small bleeding risk, and can be used as an antithrombotic or thrombolytic drug.

The invention relates to the technical field of image recognition, and discloses a carotid plaque stability and stroke risk prediction system fusing multiple modes, and the system comprises a data collection and fusion module, a feature extraction and association module, a risk assessment and layering module, an intervention decision module, and a report generation and feedback module. When carotid plaque stability and cerebral apoplexy risk prediction is carried out, plasma proteomics, radiomics and clinical data are synergistically integrated by establishing a multi-modal data fusion analysis framework, so that the limitation that a traditional method depends on a single data source is overcome; the plaque risk can be evaluated from multiple dimensions of biological activity and morphological features, the comprehensiveness and accuracy of risk prediction are improved, a more reliable diagnosis basis is provided for clinic, interaction and sensitivity influence among different modal features can be adaptively quantified by introducing dynamic feature correlation modeling and a real-time weight calibration mechanism, and the risk prediction accuracy is improved. And objectivity and consistency of risk assessment results are ensured.

The utility model discloses a full-automatic whole blood sample pretreatment device for separating plasma through immunomagnetic beads. The full-automatic whole blood sample pretreatment device comprises a plasma separation mechanism for extracting a plasma sample from a whole blood sample, a conveying mechanism for conveying a blood collection tube and a sample cup, and a feeding mechanism for providing the sample cup, the plasma separation mechanism comprises a sample loading and shaking module for uniformly mixing a whole blood sample in the blood collection tube, a puncture sampling module for collecting the whole blood sample or the plasma sample, and a magnetic separation module for separating the plasma sample; the magnetic separation module comprises an oscillation assembly, a magnetic attraction assembly and a reaction cup, and freeze-dried immunomagnetic beads and an antibody reagent are pre-stored in the reaction cup. The device provided by the utility model can be used for comprehensively and automatically pretreating a whole blood sample and improving the quality and the efficiency of plasma separation.

The present invention belongs to the field of biological detection technology, and specifically relates to an anti-monkey C-reactive protein monoclonal antibody, an enzyme-linked immunosorbent assay kit and its application. Named CRP-13, CRP-13 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region has three complementary determining regions CDR-H1 to CDR-H3, and the amino acid sequences are shown in SEQ ID NO.6-SEQ ID NO.8; the light chain variable region has three complementary determining regions CDR-L1 to CDR-L3, and the amino acid sequences are shown in SEQ ID NO.9-SEQ ID NO.11. The monoclonal antibody of the present invention can specifically bind to monkey C-reactive protein with high specificity. The above monoclonal antibody can be used to screen a paired monoclonal antibody, and a monkey C-reactive protein enzyme-linked immunosorbent assay kit is obtained based on the combination of the monoclonal antibodies, which can detect the content of monkey C-reactive protein in monkey serum, plasma or tissue fluid.

The invention relates to the field of biomedicine, and provides a cardiovascular metabolism risk factor spectrum recognition model construction system, a storage medium and a kit. The recognition model construction system for the cardiovascular metabolism risk factor spectrum comprises an acquisition module, a feature selection module, a training module and a recognition module. The model for predicting the medium-risk or high-risk type of the cardiovascular metabolism risk factor spectrum has excellent risk assessment capability of sensitivity, specificity and accuracy, only needs a small amount of plasma as a detection sample, is low in cost, is easily accepted by a subject, is suitable for large-scale popularization of the method, and has a wide application prospect. The method can also be used for screening cardiovascular metabolism risk factor spectrum drugs.

Antibiotic for use in a method comprising systemically administering a photosensitive antibiotic to a subject having a microbial infection in a target tissue to provide a blood plasma concentration of the antibiotic in the subject; allowing the plasma or tissue concentration of the antibiotic increase to a predetermined level; and subjecting the target tissue to photodynamic therapy in order to increase the antimicrobial action of the antibiotic in the target tissue. With light activation the efficacy of the photosensitizer antibiotic can be enhanced, the spectrum of the microbial effect broadened and even an antiviral effect can be obtained. Generally, the present invention can be exploited when there is a need for enhancement of the local antimicrobial effect of antibiotics.

Described are embodiments that include methods and devices for separating components from multi-component fluids. Embodiments may involve use of separation vessels and movement of components into and out of separation vessels through ports. Embodiments may involve the separation of plasma from whole blood. Also described are embodiments that include methods and devices for positioning portions, e.g., loops, of disposables in medical devices. Embodiments may involve use of surfaces for automatically guiding loops to position them into a predetermined position.

The invention includes a mutant Taq polymerase, which can effectively amplify a target sequence under conditions of salt concentration(s) similar to body fluids, including blood, serum or plasma preserved with sodium citrate. The mutant Taq polymerase, or a biologically active fragment thereof, has one or more substitutions differing from the wild type as shown in Table I.

The invention relates to the technical field of biological medicine, in particular to a wound repair material and a preparation method and application thereof.The wound repair material is in a gel shape and comprises hydrogel and platelet-rich plasma, the hydrogel is formed by dynamic crosslinking of collagen and oxidized hyaluronic acid, and the hydrogel physically encapsulates the platelet-rich plasma. The gelatinous wound repair material provides bionic mechanical support through a dynamic cross-linked network, synergistically regulates and controls an inflammation microenvironment and sequential release of PRP growth factors, remarkably promotes angiogenesis and wound healing, is suitable for the clinical treatment fields of diabetic ulcer, chronic difficult-to-heal wounds and the like, and has broad application prospects. The material has the functions of mechanical support, anti-inflammatory regulation and growth factor controlled release.

The invention relates to the technical field of aplastic anemia (AA) treatment research, discloses a biomarker method for predicting the curative effect of cyclosporine on aplastic anemia, and aims to detect plasma differential metabolites of patients with aplastic anemia by adopting a metabonomics technology, find potential biomarkers for treating AA patients and find the curative effect of cyclosporine on the AA patients. CsA) is used for treating the in-vivo metabolism of AA. The method is based on liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) technologies, and comprises the following steps: collecting 5 plasma samples of AA patients, 5 plasma samples of healthy people and 5 plasma samples of patients in a stable period after treatment for comparative analysis; and screening differential compounds by adopting a multivariate statistical method, and further performing enrichment analysis on differential metabolites. Research of the method shows that in-vivo metabolites of AA patients and healthy people are obviously different, and the way related to immunity and energy metabolism may be a key target for treating AA; csA intervenes the occurrence and development of AA by regulating and controlling immune-related metabolic ways.

The invention discloses a block chain-based blood full-process traceability tracking and safety management system and method, and relates to the technical field of blood management, and the method comprises the steps: distributing an encrypted digital identifier with a timestamp for each blood unit; collecting physical characteristic data of the blood storage environment in real time; dynamically adjusting the state mark of the blood product based on a preset plasma quality evaluation model; a threshold signature technology is adopted to ensure that multiple medical institutions complete blood information verification and sharing on the premise of protecting privacy; when it is monitored that the blood environment parameters exceed a safety threshold value, graded early warning is generated, and an emergency processing flow is started; and establishing a blood circulation whole process auditing tracking system. The system has the advantages that the blood whole-process traceability system based on the block chain is constructed, transparent credible management of the whole life cycle of blood products from collection to use is achieved, the trust and privacy protection problem in multi-mechanism cooperation is solved, and the blood safety management level and the emergency processing efficiency are comprehensively improved.

The invention relates to an adjusting system applied to continuous kidney replacement treatment of acute kidney injury patients. Comprising the following steps: capturing the blood flow velocity and vascular endothelial permeability of glomerular capillaries in real time by using a micro sensor or a nano-scale optical imaging technology; the method comprises the following steps: pre-judging a risk time point of insufficient tissue perfusion through dynamic modeling of a capillary structure and a functional relationship; combining the microcirculation data with conventional biochemical indexes of the patient to create an early intervention model; when it is monitored that microcirculation perfusion is greatly reduced or kidney oxygen supply is insufficient, continuous renal replacement therapy CRRT parameter fine adjustment is triggered in advance; the method comprises the following steps: collecting plasma toxins of different patients at clinical and molecular levels, and constructing a common toxin map of the acute kidney injury AKI; whether the specific toxin concentration exceeds the standard or not is judged by combining a real-time sensor, and the removal priority is output in real time; a membrane material with an adjustable aperture or a special coating is adopted, so that inflammatory mediators and bacterial endotoxin molecules are adsorbed or intercepted, and the permeability of micromolecular electrolyte is kept.

The invention relates to a breast cancer plasma transporter miRNA marker and application thereof, and belongs to the technical field of biological detection. In the prior art, biomarkers for breast cancer liquid biopsy have the problems of low content, high heterogeneity, insufficient time resolution and the like, so that the detection reliability is limited. According to the invention, a specific miRNA (micro Ribonucleic Acid) marker (including one or more of let-7d-5p, miR-103a-3p and miR-22-3p) of the plasma transporter is provided. The marker can be used for preparing a breast cancer detection reagent or kit. Clinical verifications show that the miRNAs are remarkably and highly expressed in plasma migrators of breast cancer patients, the AUC value reaches 0.763-0.808, the sensitivity is 66.7%-86.7%, the specificity is 66.7%-88.3%, the miRNAs have the advantages of high signal-to-noise ratio and dynamic monitoring, and the accuracy and practicability of breast cancer detection are remarkably improved.

Compositions and kits comprising enantiomerically enriched forms of MDMA, an inhibitor of CYP2D6, and a pharmaceutically acceptable carrier. Also disclosed are methods of increasing or prolonging exposure of R(-)-MDA in plasma or brain of a subject in need thereof.

The present invention relates to the field of biomedicine and discloses a platelet-rich plasma for anti-aging and promoting tissue repair and regeneration, a preparation method, and an application thereof, comprising the following steps: obtaining concentrated platelet plasma, and treating the concentrated platelet plasma with low-intensity pulsed ultrasound; the treatment conditions are one of the following treatment methods: 1) the treatment power is 2 to 5 W / cm 2 , the pulse period is 50%, and the ultrasonic treatment time is 2~10 min; 2) First, the first ultrasonic treatment is performed: using 0.2~1.0 W / cm 2 , the pulse period is 50%, ultrasonic treatment is 1~5 min; then the second ultrasonic treatment is carried out: 1.5~5.0 W / cm 2 , the pulse period is 50%, and the ultrasonic treatment is 1 to 5 minutes; the present invention adopts a special ultrasonic treatment system to obtain a PRR product with special activation and lysis characteristics. The product has active substances that are beneficial to tissue repair and regeneration and anti-aging, and shows excellent effects in promoting cell proliferation, cell migration and wound healing.

The invention discloses a blood component separation system and a control method, and belongs to the field of blood separation.The system comprises a centrifugal device, a blood supply pipeline, an air detector valve and a blood pump, a liquid outlet of the centrifugal device is connected with a separation pipeline, and the separation pipeline is sequentially connected with a first plasma bag and a second plasma bag; a centrifugal pressure sensor, a centrifugal high-speed camera and a red blood cell sensor; and the control center comprises a data acquisition module, a data analysis module and a centrifugal control module. The control method comprises steps S1 to S4. Dynamic intelligent regulation and control and automatic control of the blood component centrifugal separation system are achieved, the centrifugal effect is optimized through the image recognition technology, the image recognition technology is superior to the photoelectric recognition technology in the prior art, excessive centrifugation is avoided, meanwhile, the centrifugal quality is guaranteed, and the quality and activity of separated blood components are effectively guaranteed.

Compositions and kits comprising enantiomerically enriched forms of MDMA, an inhibitor of CYP2D6, and a pharmaceutically acceptable carrier. Also disclosed are methods of increasing or prolonging exposure of R(−)-MDA in plasma or brain of a subject in need thereof.

The invention discloses application of plasma exosomes in treatment of optic nerve retinal degeneration diseases. The invention further finds that the plasma exosome can obviously promote proliferation and function recovery of retinal ganglion cells for the first time, and can effectively improve optic nerve injury in optic nerve retinal degeneration diseases. Especially, the plasma exosome of the glaucoma patient has a more remarkable effect of improving optic nerve injury in neural retinal degeneration diseases. The plasma exosome provided by the invention is simple in preparation method, can be directly extracted from plasma, does not need a cell culture process, does not need additional components, and has the advantages of wide applicability, good safety, no animal-derived components and the like.

The invention provides a preparation method of antitoxin serum containing an horse F (ab ') 2 fragment, and the specific steps are as follows: a recombinant streptococcus immunoglobulin G degrading enzyme is immobilized to obtain an immobilized enzyme chromatography column, the recombinant streptococcus immunoglobulin G degrading enzyme comprises a glutathione-S-transferase tag and a histidine tag; performing primary treatment on the immune plasma to obtain a pretreated antibody solution; the pretreatment antibody solution is added into an immobilized enzyme chromatography column for digestion, after digestion is completed, ultrafiltration, purification and solution preparation are sequentially conducted through an immobilized glutathione affinity column or a nickel affinity column, an antitoxin serum stock solution is obtained, and the antitoxin serum stock solution contains F (ab ') 2 fragments and does not contain Fc fragments, impure protein and small molecule impurities. Through the process steps, the Fc fragment and impure protein are effectively removed, and only the horse F (ab ') 2 fragment is reserved, so that the immunogenicity of antitoxin serum and the risk of causing anaphylactic reaction are remarkably reduced.

The present invention is directed to a variant of a parent polypeptide containing an Fc region of a dog or cat IgG, that shows a higher binding activity to a dog or cat neonatal Fc receptor (FcRn) than a binding activity of the parent polypeptide to a dog or cat FcRn, wherein the Fc region contains at least one amino acid modification. The variant shows an enhanced FcRn binding activity under acidic conditions. Using the variant, therefore, an antibody (IgG) and Fc fusion protein having longer retention in plasma can be provided.

The invention relates to a virus DNA and RNA co-extraction kit and an extraction method, and belongs to the technical field of biology. By matching the lysate, the rinsing liquid and other solutions with the extraction method, the method can directly extract viral nucleic acids (DNA and RNA) in cell-free body fluids of human and animals, such as centrifugal supernatant of serum, plasma and tissue grinding fluid. According to the method and the kit, DNA and RNA can be extracted at the same time, operation is easy, particularly, the nucleic acid extraction sensitivity of the small viruses is high, and the extraction effect is better.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

The invention discloses a magnetic control liquid drop micro-fluidic chip, device and method for chemiluminescence immunoassay, and belongs to the technical field of chemiluminescence immunoassay, the micro-fluidic chip comprises: a chip main body, which comprises a plurality of vertically through separation chambers for loading a reagent and serving as a reaction container, if the chip has the function of separating plasma from the whole blood sample, the first cavity adopts a bottom closed structure, and no gap is formed in the separation position between the first cavity and the second cavity; the top thin film and the bottom thin film are used for sealing the separated cavity of the chip main body; and the top gland and the bottom gland are matched with the chip main body in structural shape and are used for firmly attaching the two layers of films to the chip main body. According to the invention, the whole process integration of sample pretreatment, reagent mixing, reaction incubation and chemiluminescence detection can be realized, and a chemiluminescence immunoassay solution which is efficient, low in cost and easy to operate is provided through chip design, device integration and method optimization.

The invention relates to an application of Danjie emodin in preparation of drugs for preventing or treating drug-induced liver injury. The liver injury is drug-induced liver injury induced by acetaminophen. According to the invention, the effective component Danleaf emodin in the traditional Chinese medicine rhubarb is used for preventing and treating drug-induced liver injury induced by acetamido, and the traditional Chinese medicine composition has the characteristics of safety, reliability and small toxic and side effects. Starting from the whole, multi-target intervention is performed on drug-induced liver injury induced by acetaminophen, the levels of glutamic-pyruvic transaminase, glutamic oxalacetic transaminase and malondialdehyde in plasma are remarkably reduced, the obvious anti-inflammatory and liver cell apoptosis inhibiting effects are achieved, the good clinical application prospect is achieved, and a new way is provided for prevention and treatment of liver injury.

The invention discloses application of small extracellular endovesicular protein as a prostatic cancer diagnostic marker, and is characterized in that the small extracellular endovesicular protein is plasma sample sEV protein LAMB1 and / or urine sample sEV protein Histone H4, and the plasma sample sEV protein LAMB1 is applied as a metastatic prostatic cancer diagnostic marker. The sEV protein LAMB1 of the plasma sample is combined with a prostate specific antigen to serve as metastatic prostate cancer; the application of the sEV protein Histone H4 in the urine sample as a prostate cancer grading diagnosis marker, the application of the sEV protein Histone H4 in the urine sample as a high-risk prostate cancer diagnosis marker and the application of the combination of the sEV protein Histone H4 in the urine sample and a prostate specific antigen as the high-risk prostate cancer diagnosis marker have the advantages of high sensitivity and strong specificity.